Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Withdraws Zimulti NDA For Weight Loss

This article was originally published in The Pink Sheet Daily

Executive Summary

Company cites confusion over concerns raised by the Endocrinologic and Metabolic Drugs Advisory Committee, which voted against approval June 13.

You may also be interested in...



Cannabinoid Market Snapshot: GW's Epilepsy Success Bodes Well

Over 50 cannabinoid drugs are in development, most commonly targeting central nervous system diseases. Analysts think the relaxation of restrictions on medical cannabis is helping with perception problems, but so far there’s little evidence the market isn’t just smoke and mirrors.

FDA, Orexigen Discussing CV Risk Study For Weight-Loss Drug Contrave

Timing of the study to be discussed at Dec. 7 advisory committee meeting.

FDA, Orexigen Discussing CV Risk Study For Weight-Loss Drug Contrave

Timing of the study to be discussed at Dec. 7 advisory committee meeting.

Related Content

Topics

UsernamePublicRestriction

Register

PS066259

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel